Mirati Therapeutics, Inc. (NASDAQ:MRTX) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET

Company Participants

Ryan Asay - Vice President of Corporate Affairs

David Meek - Chief Executive Officer

Chuck Baum - President, Founder & Head of Research & Development

Laurie Stelzer - Chief Financial Officer

Jamie Christensen - Chief Scientific Officer

Ben Hickey - Chief Commercial Officer

Conference Call Participants

Michael Schmidt - Guggenheim

Tyler Van Buren - Cowen

Jonathan Miller - Evercore

Ben Burnett - Stifel

Andrew Berens - SVB Securities

Evan Seigerman - BMO Capital Markets

Yigal Nochomovitz - Citi

Mike Ulz - Morgan Stanley

Maury Raycroft - Jefferies

Jay Olson - Oppenheimer

Operator

Good afternoon, and welcome to the Mirati Therapeutics Second Quarter 2022 Earnings Call. My name is Danielle, and I will be the operator for today's call. All lines have been placed on mute to prevent any background noise. After the conclusion of the speakers prepared remarks. There will be a question-and-answer session. [Operator Instructions]

It is now my pleasure to introduce Ryan Asay, Vice President of Corporate Affairs at Mirati. Ryan, please go ahead.

Ryan Asay

Thank you, Danielle, and welcome everyone to this afternoon's call. Joining me on the call today are David Meek, Mirati's Chief Executive Officer; Dr. Chuck Baum, Mirati's President Founder and Head of Research and Development; and Laurie Stelzer, Mirati's Chief Financial Officer. Dr. Jamie Christensen, Mirati's Chief Scientific Officer; and Ben Hickey, Maruti's Chief Commercial Officer are also with us and will be available for the Q&A portion of the call.

Please note that, this conference call will include forward-looking statements. Because such statements deal with future events and are subject to many risks and uncertainties actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 10-K, and our quarterly reports on Form 10-Q that are filed with the US Securities and Exchange Commission.

This afternoon, we released financial results for the quarter ended June 30, 2022 and recent corporate updates. This press release is available on the Investors section of our website at mirati.com.

With that, David I'll turn the call over to you.

David Meek

Thank you, Ryan, and good afternoon, everyone. On this attorney's call, I'll provide an update on key developments, since our last earnings call, including steps we’re taking to prepare for a potential commercial launch of out aggressive this year. Chuck will share an update on our R&D programs. And Laurie, our recently appointed CFO, will summarize our financial results. I'll then provide closing remarks, before we open the line for questions.